Development of a Therapeutic Anti-Dengue Polymeric IgG Antibody

Key facts

Disease
Dengue
Start & end year
2021
2023
Known Financial Commitments (USD)
$191,072.25
Funder
RIGHT Foundation
Principal Investigator
N/A
Research Location
41, 41
Lead Research Institution
St George's University of London (SGUL)
Research Priority Alignment
N/A

Research Category
N/A
Research Subcategory
N/A
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable

Abstract

In order to eliminate the risk of antibody dependent enhancement (ADE), St. George's University of London is developing a polymeric anti-dengue IgG construct with LALA mutation, in collaboration with Jeonbuk National University and Genecell Biotech. The project aims to develop an innovative polymeric antibody construct that is superior to conventional neutralizing monoclonal IgG antibodies. The new plant-based protein expression system promises broader applications for reducing manufacturing price, thereby making antibody therapies accessible to patients in LMICs.